98%
921
2 minutes
20
Background: Coronavirus disease 2019 (COVID-19) was previously thought to have a low reinfection rate, but there are concerns that the reinfection rate will increase with the emergence and spread of mutant variants. This report describes the case of a 36-year-old, non-immunosuppressed man who was infected twice by two different variants of COVID-19 within a relatively short period.
Case Presentation: A 36-year-old Japanese man with no comorbidities was infected with the E484K variant (R.1 lineage) of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Symptoms were mild and improved with symptomatic treatment alone. About four months later he presented to another outpatient department with high fever and headache. We diagnosed him as infected with the Alpha variant (B.1.1.7) of SARS-CoV-2 based on SARS-CoV-2 real-time reverse transcription polymerase chain reaction testing (RT-PCR). The patient was hospitalized with high fever. The patient received treatment in the form of anti-inflammatory therapy with corticosteroid and antibacterial chemotherapy. The patient improved without developing severe disease.
Conclusion: Concerns have been raised that the reinfection rate of COVID-19 will increase with the emergence of mutant variants. Particularly in mild cases, adequate amounts of neutralizing antibodies may not be produced, and reinfection may thus occur. Continued attention to sufficient infection control is thus essential.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9907179 | PMC |
http://dx.doi.org/10.1186/s43162-023-00194-4 | DOI Listing |
Hepatitis C (HCV) infection is a major global health challenge, with particularly high prevalence among people who inject drugs (PWID) in the Eastern European and Central Asian region (EECA). While the country of Georgia has made major progress in reducing overall HCV prevalence, less is known about HCV reinfection rates and risk factors for reinfection among PWID. In this study, we aimed to: (1) estimate HCV reinfection rates and (2) identify risk factors associated with HCV reinfection among PWID.
View Article and Find Full Text PDFBMJ Public Health
August 2025
Epidemiology and Data Management Unit, Division of Intramural Research, National Institute of Allergy and Infectious Diseases Division of Intramural Research, Bethesda, Maryland, USA.
Introduction: Immune-deficient/disordered people (IDP) elicit a less robust immune response to COVID-19 vaccination than the general US population. Despite millions of IDP at presumed elevated risk, few population-level studies of IDP have been conducted in the Omicron era to evaluate breakthrough infection-related outcomes.
Methods: We followed a prospective cohort of 219 IDP and 63 healthy volunteers (HV) in the USA from April 2021 (Alpha variant peak) to July 2023 (Omicron XBB variant peak).
Trop Med Health
September 2025
RIKEN Center for Integrative Medical Sciences, 1-7-22 Suehiro-cho, Tsurumi-ku, Yokohama, Kanagawa, 230-0045, Japan.
Background: Schistosomiasis is a neglected tropical disease caused by parasitic flatworms of the genus Schistosoma. Currently, praziquantel is the only medication available for treating schistosomiasis. However, crucial issues regarding drug resistance, reinfection, and prevention remain unresolved.
View Article and Find Full Text PDFJ Arthroplasty
August 2025
Department of Orthopedic Surgery, University of Heidelberg, Schlierbacher Landstrasse 200a, 69118 Heidelberg, Germany.
Purpose: The purpose of this study was to evaluate the clinical, functional, and radiographic outcomes in patients who underwent two-stage cementless arthrodesis following multiple revision surgeries for periprosthetic joint infection (PJI), after a mean follow-up of 57.0 months (range, two to 208).
Methods: From 2002 to 2012, 31 patients underwent a two-stage revision for PJI using an intramedullary modular arthrodesis system.
AIDS Res Ther
August 2025
bioLytical Laboratories Inc, Richmond, Canada.
Background: Syphilis poses a significant threat to global health, particularly in high-risk populations and resource-limited settings. Despite progress in HIV screening, syphilis testing often lags, exacerbating disparities in healthcare delivery. This study evaluated the clinical performance of the iStatis Syphilis Antibody (Ab) Test in South African point-of-care environments.
View Article and Find Full Text PDF